Deferring Surgery With Zimmer Biomet's Early Intervention Treatment

Zimmer Biomet’s nSTRIDE® is an early intervention knee treatment is designed to help restore balance in a progressing osteoarthritic (OA) knee.

The company’s novel system, which introduces high levels of anti-inflammatory proteins into the joint, concentrates the protein solution from the patient’s own blood for a single injection treatment. It is used to mitigate symptoms of knee pain and inflammation and may contribute to preserving the health of native cartilage.

Patients who respond to the treatment will experience a slower progression in knee OA disease, as the treatment reduces pain and inflammation in the joint, which leads to functional improvement. When patients regain function, they defer surgery as long as function is maintained, which means that during this time they are not taking up a surgical spot, while also helping to ensure their quality of life.

The Covid-19 pandemic has had an exacerbating effect on the access to care for knee OA, resulting in increased wait times. Many Sports Medicine Clinics in BC, Alberta, Saskatchewan, Ontario, and Quebec have adopted Zimmer Biomet’s technology to help patients manage early knee OA.

For more information: https://nstride.zimmerbiomet.com/canada/